Neonatal Respiratory Distress Syndrome Treatment MarketSize and Trends

Neonatal Respiratory Distress Syndrome Treatment Market - Drivers

The increasing prevalence of neonatal respiratory distress syndrome is expected to facilitate the market growth. According to the U.S National Library of Medicine, in 2015, neonatal respiratory distress syndrome was found in 6 to 7% neonates in the U.S. Therefore, there is potential opportunity for pharmaceutical companies to expand their presence in the neonatal respiratory distress syndrome treatment market. Thus, pharmaceutical companies are focusing on mergers and acquisitions to achieve growth and make profits in neonatal respiratory distress syndrome treatment market. For instance, in 2017, Aerogan Pharmaceuticals and Lyomark Pharmaceuticals merged with the aim of developing AP-002, a clinically superior treatment for neonatal respiratory distress syndrome. These factors are expected to drive the neonatal respiratory distress syndrome treatment market growth.

Neonatal Respiratory Distress Syndrome Treatment Market - Impact of COVID-19

Patients with respiratory distress syndrome are at severe risk of COVID-19. Whereas, in case neonates with respiratory distress syndrome are at minimal risk due to COVID-19 compared to adults due to less chance of community transmission. However, there is a chance of getting infected in the womb or due to close contact with an infected adult. On the other hand, surfactant therapy and mechanical ventilation are some of the efficient treatments for neonatal distress syndrome in COVID-19 patients. As a result, the global neonatal respiratory distress syndrome treatment market is expecting to experience moderate growth during the pandemic.

Neonatal Respiratory Distress Syndrome Treatment Market- Restraints.

Oxygen therapy and mechanical ventilation therapy is associated with common risk of pneumonia in neonates due to difficulty in breathing and coughing caused by breathing tube. In surfactant therapy, there is risk of bradycardia, hypoxemia during instillation in neonates. Moreover, the cost of neonatal ventilation is high and may be unaffordable for many patients in under developed countries such as India. These factors are expected to restrain global neonatal respiratory distress syndrome treatment market growth.

Neonatal Respiratory Distress Syndrome Treatment Market - Taxonomy

By Treatment Type-
- Continuous Positive Airway Pressure Therapy
- Surfactant Therapy
- Neonatal Ventilation
By End User-
- Hospital
- Clinics
- Ambulatory Care Centres
By Region-
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa